| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 320,400 | 74,600 | 188,400 | 614,400 |
| Amortization of intangible assets | 277,800 | 182,900 | 91,300 | 277,800 |
| Depreciation | 87,200 | 57,600 | 28,700 | 80,600 |
| Impairment of goodwill and other intangible assets | 265,800 | 265,800 | - | - |
| Non-cash restructuring charges | 0 | - | - | 1,600 |
| Stock-based compensation expense | 45,800 | 30,900 | 14,200 | 43,600 |
| Loss on equity method investments | -127,100 | -127,100 | -6,200 | -19,000 |
| Foreign currency transaction losses, net | -15,600 | -12,800 | -6,800 | -9,200 |
| Non-cash adjustments to carrying value of lifo inventories | 15,500 | 10,300 | 3,000 | 7,200 |
| Loss on extinguishment of debt | 0 | 0 | - | -3,000 |
| Loss on sale of asbestos-related assets and liabilities | 0 | 0 | - | -33,700 |
| Other non-cash adjustments | -7,200 | -4,800 | -2,400 | -5,200 |
| Receivables | -23,300 | -38,300 | -25,300 | 17,900 |
| Inventories | 109,600 | 86,000 | 54,100 | 40,100 |
| Accounts payable | -69,200 | -44,200 | -70,400 | -95,600 |
| Accrued liabilities | 3,300 | -50,600 | 39,700 | 5,000 |
| Other assets and liabilities, net | 153,500 | 122,200 | 25,100 | 76,200 |
| Net cash provided by operating activities | 856,700 | 502,100 | 256,400 | 870,500 |
| Capital expenditures | 98,100 | 69,000 | 33,700 | 113,800 |
| Net cash paid in acquisitions | 459,800 | 210,400 | 163,400 | 2,759,100 |
| Disposals of property, plant and equipment | 0 | - | - | 6,100 |
| Other investing | 0 | 0 | - | 6,000 |
| Net cash used in investing activities | -557,900 | -279,400 | -197,100 | -2,872,800 |
| Principal payments on long-term debt | 0 | 0 | 0 | 1,241,800 |
| Proceeds from long-term debt | 0 | 0 | - | 3,296,900 |
| Purchases of treasury stock | 703,300 | 510,200 | 10,000 | 198,200 |
| Cash dividends on common shares | 24,000 | 16,100 | 8,100 | 24,200 |
| Proceeds from stock option exercises | 12,800 | 9,100 | 5,200 | 28,300 |
| Payments to settle cross-currency swaps | 0 | 0 | - | 19,900 |
| Payments of deferred and contingent acquisition consideration | 6,200 | 2,800 | 1,400 | 22,600 |
| Payments of debt issuance costs | 0 | 0 | - | 32,300 |
| Other financing | -5,900 | -3,100 | 4,300 | -3,500 |
| Net cash provided by (used in) financing activities | -726,600 | -523,100 | -10,000 | 1,782,700 |
| Effect of exchange rate changes on cash and cash equivalents | 63,200 | 69,800 | 22,300 | 1,000 |
| Net decrease in cash and cash equivalents | -364,600 | -230,600 | 71,600 | -218,600 |
| Cash and cash equivalents at beginning of period | 1,541,200 | 1,541,200 | 1,541,200 | 1,595,500 |
| Cash and cash equivalents at end of period | 1,176,600 | 1,310,600 | 1,612,800 | 1,376,900 |
Ingersoll Rand Inc. (IR)
Ingersoll Rand Inc. (IR)